Sotatercept Phase 3 Trial NCT07218029 Now Recruiting for PAH

On August 21, 2026, a Phase 3 clinical trial update was recorded for sotatercept, also known as MK-7962. The study, titled "A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)," is registered under identifier NCT07218029. According to ClinicalTrials.gov, the trial status is listed as recruiting. The study is designated as a Phase 3 trial, indicating it is in a later stage of clinical investigation for pulmonary arterial hypertension. No results have been posted for this trial as of the listed date. This update reflects only the recruitment status and phase classification as recorded in the trial registry. No efficacy or safety outcomes are included in this update. Nesiritide is noted here as unapproved and intended for research use only, separate from the sotatercept trial referenced. Readers interested in additional detail can consult the official trial listing directly for enrollment criteria and further trial design information. For broader background on sotatercept as a compound, readers can refer to the compound overview page for additional context.